Streamlining Medicaid Fasenra Prior Authorization Workflows

Understanding Fasenra and Medicaid Coverage Dynamics

Fasenra (benralizumab) is a biologic medication, specifically an interleukin-5 (IL-5) receptor alpha-directed cytolytic monoclonal antibody, indicated for the add-on maintenance treatment of severe eosinophilic asthma in patients 12 years and older. As a high-cost specialty medication, Fasenra is consistently a target for prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Medicaid coverage for Fasenra is subject to state-specific formularies and medical necessity criteria, often requiring documentation of severe eosinophilic asthma and prior failure of other therapies.

Medicaid's Dual PA Landscape: Fee-for-Service (FFS) vs. Managed Care Organizations (MCOs)

Medicaid services are delivered through two primary models: Fee-for-Service (FFS), where the state Medicaid agency directly administers benefits, and Medicaid Managed Care, where states contract with MCOs (e.g., Centene subsidiaries, Molina, UHC Community Plan, Anthem Medicaid plans) to manage care. The vast majority of Medicaid beneficiaries are enrolled in managed care. Prior authorization requirements for Fasenra, therefore, vary significantly by state and by the specific MCO responsible for the member's benefits, with MCOs typically having their own provider portals and specific criteria that must align with, but cannot be more restrictive than, state Medicaid policy.

Key Considerations for Fasenra Prior Authorization Under Medicaid

• **State-Specific Criteria:** Each state Medicaid agency publishes its medical necessity criteria, which MCOs must adhere to as the baseline for Fasenra approval.
• **Formulary and Step Therapy:** Fasenra is often placed on higher formulary tiers, typically requiring documentation of previous treatment failures (step therapy) with less costly asthma medications.
• **Eosinophil Count Documentation:** Approval frequently hinges on documented elevated eosinophil counts, confirming the severe eosinophilic asthma phenotype.
• **Medical Necessity Documentation:** Comprehensive clinical notes detailing diagnosis, severity, previous treatments, and patient response are critical for successful submissions.
• **MCO-Specific Requirements:** Beyond state guidelines, each Medicaid MCO may have unique submission forms, portal workflows, and documentation preferences for specialty drugs like Fasenra.

Operational Channels for Medicaid Fasenra PA Submissions

Submitting Fasenra prior authorizations under Medicaid requires navigating diverse operational channels. For FFS Medicaid, submissions typically route through the state Medicaid agency's fiscal agent or dedicated state portal. For Medicaid Managed Care members, submissions are directed to the responsible MCO's provider portal. While X12 278 electronic prior authorization routing is supported by some payers, a significant volume of specialty drug PAs still necessitate manual portal-based submissions, adding complexity to high-volume drugs like Fasenra.

Klivira's Approach to Medicaid Specialty Drug PAs

Klivira's platform is engineered to address the complexities of Medicaid Fasenra prior authorization. Our system intelligently identifies whether a member falls under a Fee-for-Service model or a specific Medicaid Managed Care Organization. We then apply the relevant state Medicaid agency rules as the foundational criteria, while also accounting for MCO-specific requirements. For dual-eligible Medicare + Medicaid members, Klivira coordinates D-SNP requirements, ensuring comprehensive coverage assessment. Our integrations streamline the submission process, reducing manual data entry and optimizing workflow efficiency for specialty medications.

Navigating Denials and Appeals for Fasenra Under Medicaid

Common reasons for Fasenra PA denials under Medicaid often include insufficient documentation of medical necessity, failure to meet step therapy requirements, or inadequate proof of severe eosinophilic asthma with elevated eosinophils. Klivira aids in proactively addressing these challenges by ensuring submissions are complete and aligned with payer criteria. When denials occur, our system supports efficient appeal pathways, helping clinics compile necessary additional information and resubmit documentation to overturn unfavorable decisions, thereby minimizing treatment delays.